A detailed history of Headlands Technologies LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Headlands Technologies LLC holds 5,592 shares of REGN stock, worth $3.92 Million. This represents 0.7% of its overall portfolio holdings.

Number of Shares
5,592
Holding current value
$3.92 Million
% of portfolio
0.7%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1024.09 - $1201.76 $5.73 Million - $6.72 Million
5,592 New
5,592 $5.88 Million
Q1 2024

May 07, 2024

SELL
$902.69 - $993.35 $359,270 - $395,353
-398 Reduced 32.02%
845 $813,000
Q4 2023

Feb 02, 2024

BUY
$775.18 - $881.7 $959,672 - $1.09 Million
1,238 Added 24760.0%
1,243 $1.09 Million
Q3 2023

Nov 09, 2023

BUY
$692.45 - $844.37 $3,462 - $4,221
5 New
5 $4,000
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $2.28 Million - $2.48 Million
3,235 New
3,235 $2.33 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Headlands Technologies LLC Portfolio

Follow Headlands Technologies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headlands Technologies LLC with notifications on news.